Fate Therapeutics announced this week that Dan Shoemaker has been named chief technology officer.
Shoemaker was most recently chief scientific officer of ICx Biosystems. From 2003 to 2005, he was chief scientific officer of GHC Technologies, where he led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Shoemaker held several positions at Merck Research Laboratories, including director of target discovery, senior director at Rosetta Inpharmatics, and research fellow in the department of molecular neurosciences.